Iovance (IOVA) Shares New Amtagvi Data, Analysts Stay Positive

Core Insights - Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is recognized as one of the best American penny stocks to invest in, with a Buy rating and a price target of $9 from H.C. Wainwright [1][2] - The company announced data on February 5 showing that its therapy Amtagvi (lifileucel) achieved unprecedented response rates in a real-world study for patients with advanced melanoma [2][3] - Amtagvi is the first one-time T cell therapy approved by the FDA for solid tumor cancer, specifically for advanced melanoma patients previously treated with anti-PD-1 and targeted therapies [3] Analyst Ratings - Barclays reiterated an Overweight rating on Iovance Biotherapeutics, Inc. with a price target of $10 [4] - Analysts remain positive about Iovance's potential in the biotechnology sector, particularly in developing tumor-infiltrating lymphocyte (TIL) therapies for cancer patients [4]